Interleukin 35 Synovial Fluid Levels Are Associated with Disease Activity of Rheumatoid Arthritis
Jazyk angličtina Země Spojené státy americké Médium electronic-ecollection
Typ dokumentu srovnávací studie, časopisecké články, práce podpořená grantem
PubMed
26204444
PubMed Central
PMC4512689
DOI
10.1371/journal.pone.0132674
PII: PONE-D-15-13352
Knihovny.cz E-zdroje
- MeSH
- antirevmatika terapeutické užití MeSH
- biologické markery MeSH
- dospělí MeSH
- glukokortikoidy terapeutické užití MeSH
- imunosupresiva terapeutické užití MeSH
- interleukiny analýza krev fyziologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- revmatoidní artritida farmakoterapie metabolismus MeSH
- stupeň závažnosti nemoci MeSH
- synoviální tekutina chemie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- srovnávací studie MeSH
- Názvy látek
- antirevmatika MeSH
- biologické markery MeSH
- glukokortikoidy MeSH
- imunosupresiva MeSH
- interleukin-35, human MeSH Prohlížeč
- interleukiny MeSH
OBJECTIVES: To study the association of systemic and local interleukin-35 (IL-35) levels in rheumatoid arthritis. METHODS: 37 patients with treatment naïve early RA, 49 with established RA and 29 control patients with osteoarthritis (OA) were studied. Serum and paired synovial fluid samples were analysed for IL-35. Disease activity of RA patients was assessed according to the 28-Joint Count Disease Activity Score (DAS28). RESULTS: The levels of serum IL-35 were significantly higher in patients with treatment naïve early RA compared to those with established disease and control OA subjects. In addition, serum levels of IL-35 significantly decreased 12 weeks after initiation of glucocorticoids and conventional synthetic disease modifying antirheumatic drugs in patients with treatment naïve early RA. Synovial fluid IL-35 levels were significantly higher in RA compared to OA patients, were significantly elevated compared to serum counterparts and correlated with synovial fluid leukocyte count (r=0.412; p<0.01), serum CRP levels (r=0.362; p<0.05) and DAS28 (r=0.430, p<0.01). CONCLUSION: This is the first study showing elevated circulating levels of IL-35 in treatment naïve early RA, its significant decrease after treatment initiation and positive association between increased synovial fluid IL-35 and disease activity in patients with long-lasting RA.
Zobrazit více v PubMed
Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376:1094–108. 10.1016/S0140-6736(10)60826-4 PubMed DOI
McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7:429–42. PubMed
Ospelt C, Gay S. The role of resident synovial cells in destructive arthritis. Best Pract Res Clin Rheumatol. 2008;22:239–52. 10.1016/j.berh.2008.01.004 PubMed DOI
Senolt L, Vencovský J, Pavelka K, Ospelt C, Gay S. Prospective new biological therapies for rheumatoid arthritis. Autoimmun Rev. 2009;9:102–7. 10.1016/j.autrev.2009.03.010 PubMed DOI
McInnes IB, O'Dell JR. State-of-the-art: rheumatoid arthritis. Ann Rheum Dis. 2010;69:1898–906. 10.1136/ard.2010.134684 PubMed DOI
Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al.; T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631–7. 10.1136/ard.2009.123919 PubMed DOI PMC
Collison LW, Vignali DA. Interleukin-35: odd one out or part of the family? Immunol Rev. 2008;226:248–62. 10.1111/j.1600-065X.2008.00704.x PubMed DOI PMC
Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 2007;450:566–9. PubMed
Wirtz S, Billmeier U, Mchedlidze T, Blumberg RS, Neurath MF. Interleukin-35 mediates mucosal immune responses that protect against T-cell-dependent colitis. Gastroenterology. 2011;141:1875–86. 10.1053/j.gastro.2011.07.040 PubMed DOI PMC
Kuo J, Nardelli DT, Warner TF, Callister SM, Schell RF. Interleukin-35 Enhances Lyme Arthritis in Borrelia-Vaccinated and-Infected Mice. Clin Vaccine Immunol. 2011;18:1125–32. 10.1128/CVI.00052-11 PubMed DOI PMC
Thiolat A, Denys A, Petit M, Biton J, Lemeiter D, Herve R, et al. Interleukin-35 gene therapy exacerbates experimental rheumatoid arthritis in mice. Cytokine. 2014. September;69(1):87–93. 10.1016/j.cyto.2014.05.015 PubMed DOI
Filková M, Vernerová Z, Hulejová H, Prajzlerová K, Veigl D, Pavelka K, et al. Pro-inflammatory effects of interleukin-35 in rheumatoid arthritis. Cytokine. 2015. February 16;73(1):36–43. 10.1016/j.cyto.2015.01.019 PubMed DOI
Kim W, Min S, Cho M, Youn J, Min J, Lee S, et al. The role of IL-12 in inflammatory activity of patients with rheumatoid arthritis (RA). Clin Exp Immunol. 2000;119:175–81. PubMed PMC
Melis L, Vandooren B, Kruithof E, Jacques P, De Vos M, Mielants H, et al. Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis. Ann Rheum Dis. 2010;69:618–23. 10.1136/ard.2009.107649 PubMed DOI
Wong CK, Chen da P, Tam LS, Li EK, Yin YB, Lam CW. Effects of inflammatory cytokine IL-27 on the activation of fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Res Ther. 2010;12:R129 10.1186/ar3067 PubMed DOI PMC
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580–8. 10.1136/ard.2010.138461 PubMed DOI
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315–24. PubMed
Gu X, Tian T, Zhang B, Liu Y, Yuan C, Shao L, et al. Elevated plasma interleukin-35 levels predict poor prognosis in patients with non-small cell lung cancer. Tumour Biol. 2015. April;36(4):2651–6. 10.1007/s13277-014-2887-8 PubMed DOI
Jin P, Ren H, Sun W, Xin W, Zhang H, Hao J. Circulating IL-35 in pancreatic ductal adenocarcinoma patients. Hum Immunol. 2014. January;75(1):29–33. 10.1016/j.humimm.2013.09.018 PubMed DOI
Zeng JC, Zhang Z, Li TY, Liang YF, Wang HM, Bao JJ, et al. Assessing the role of IL-35 in colorectal cancer progression and prognosis. Int J Clin Exp Pathol. 2013. August 15;6(9):1806–16. PubMed PMC
Jafarzadeh A, Jamali M, Mahdavi R, Ebrahimi HA, Hajghani H, Khosravimashizi A, et al. Circulating Levels of Interleukin-35 in Patients with Multiple Sclerosis: Evaluation of the Influences of FOXP3 Gene Polymorphism and Treatment Program. J Mol Neurosci. 2015. April;55(4):891–7. 10.1007/s12031-014-0443-z PubMed DOI
Ouyang H, Shi YB, Liu ZC, Wang Z, Feng S, Kong SM, et al. Decreased interleukin 35 and CD4+EBI3+ T cells in patients with active systemic lupus erythematosus. Am J Med Sci. 2014. August;348(2):156–61. 10.1097/MAJ.0000000000000215 PubMed DOI
Li Y, Wang Y, Liu Y, Wang Y, Zuo X, Li Y, et al. The possible role of the novel cytokines il-35 and il-37 in inflammatory bowel disease. Mediators Inflamm. 2014;2014:136329 10.1155/2014/136329 PubMed DOI PMC